Mitotherapeutix, LLC

Woodbridge, CT

UEI
QNXLAMDAM5Y4
CAGE
7J4Y3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
4 Research Dr, Woodbridge, CT 06525, USA
Founded
2014
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Industrials
  2. Commercial & Professional Services
  3. Professional Services
  4. Research & Consulting Services
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Novel treatment for alcohol-associated liver disease R41AA030517 National Institute on Alcohol Abuse and Alcoholism (NIH) $273,918
A novel approach to treat non-alcoholic steatohepatitis (nash) R44DK129102 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $2,628,391
A novel therapeutic to address fatty liver in post-parturient dairy cows 20203361031988 Institute of Food Production and Sustainability (NIFA) $30,897
A novel treatment for acetominophen-induced liver injury R41DK117760 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $264,238
A novel approach to treat non-alcoholic steatohepatitis (nash) R41DK112429 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $317,953

Similar vendors

Vendor Location Primary NAICS
Janusq LLC UEI DKRHA61KMNX4 Rocky River, OH —

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Mitotherapeutix, LLC is a biotechnology company that develops novel therapeutics targeting mitochondrial metabolism to treat various diseases. They specialize in developing siRNA drugs that can increase mitochondrial respiration and fatty acid oxidation.

Mitotherapeutix, LLC has received several federal grant awards for developing novel treatments for alcohol-associated liver disease (ALD) and non-alcoholic steatohepatitis (NASH). Their lead therapeutic candidate, MITO-1041, is a GalNAc-linked siRNA drug that targets the MCJ protein, a negative regulator of the electron transport chain (ETC) in mitochondria. By inhibiting MCJ, MITO-1041 aims to enhance mitochondrial metabolism and increase the degradation of fatty acids, thereby preventing the accumulation of fat in the liver. The National Institute on Alcohol Abuse and Alcoholism and the National Institute of Diabetes and Digestive and Kidney Diseases have awarded Mitotherapeutix grants totaling over $2.9 million to test the feasibility of MITO-1041 in treating ALD and NASH, and to conduct IND-enabling studies for the drug. Additionally, the company received a grant from the National Institute of Food and Agriculture to develop a novel therapeutic for fatty liver in post-parturient dairy cows, further demonstrating their expertise in targeting mitochondrial metabolism for various disease applications.

Quick answers

Is Mitotherapeutix, LLC registered in SAM.gov?

Yes. Mitotherapeutix, LLC's SAM.gov registration is active through May 8, 2027.

What is Mitotherapeutix, LLC's most recent federal award?

Mitotherapeutix, LLC's most recent federal grant award is Novel treatment for alcohol-associated liver disease (R41AA030517), from National Institute on Alcohol Abuse and Alcoholism (NIH), on April 1, 2023.

On GovTribe

See Mitotherapeutix, LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login